0000950170-23-007858.txt : 20230314 0000950170-23-007858.hdr.sgml : 20230314 20230314160347 ACCESSION NUMBER: 0000950170-23-007858 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230310 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230314 DATE AS OF CHANGE: 20230314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 23730690 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 8-K 1 xene-20230310.htm 8-K 8-K
0001582313false00015823132023-03-102023-03-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2023

 

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Canada

001-36687

98-0661854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

200-3650 Gilmore Way

Burnaby, British Columbia, Canada

 

V5G 4W8

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 484-3300

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Shares, without par value

 

XENE

 

The Nasdaq Stock Market LLC
(The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Adoption of Incentive Compensation Plan

On March 10, 2023, the compensation committee (the “Committee”) of the board of directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company”) adopted the Executive Incentive Compensation Plan (the “Incentive Compensation Plan”). The Incentive Compensation Plan allows the Company to grant incentive awards, generally payable in cash, to employees selected by the administrator of the Incentive Compensation Plan, including the Company’s named executive officers, based upon performance goals established by the administrator.

Under the Incentive Compensation Plan, the administrator determines the performance goals applicable to any award, which goals may include, without limitation, goals related to research and development milestones, regulatory milestones or regulatory-related goals, gross margin, financial milestones, stock price, total shareholder return, growth in shareholder value relative to the moving average of the S&P 500 Index or another index, new product invention or innovation, business development, operating margin, product release timelines or other product release milestones, publications, cash flow, cash position, procurement, savings, internal structure, leadership development, project function or portfolio-specific milestones, license or research collaboration agreements, capital raising, patentability, other Company, subsidiary, divisional or unit objectives, and individual objectives such as peer reviews or other subjective or objective criteria. The performance goals may differ from participant to participant and from award to award.

A committee appointed by the Board (which, until the Board determines otherwise, will be the Committee) administers the Incentive Compensation Plan. The Board may administer the Incentive Compensation Plan concurrently with the Committee or revoke the delegation of some or all authority previously delegated. The administrator of the Incentive Compensation Plan may, in its sole discretion and at any time, increase, reduce or eliminate a participant’s actual award, and/or increase, reduce or eliminate the amount allocated to the bonus pool for a particular performance period. The actual award may be below, at or above a participant’s target award, in the discretion of the administrator. The administrator may determine the amount of any increase, reduction or elimination on the basis of such factors as it deems relevant, and it is not required to establish any allocation or weighting with respect to the factors it considers.

Actual awards generally will be paid in cash (or its equivalent) only after they are earned, and, unless otherwise determined by the administrator, to earn an actual award, a participant must be employed by the Company through the date the actual award is paid. Payment of awards occurs as soon as practicable after they are earned, but no later than the dates set forth in the Incentive Compensation Plan.

The Board and the administrator have the authority to amend, suspend or terminate the Incentive Compensation Plan, provided such action does not impair the existing rights of any participant with respect to any earned awards.

The above description of the material terms of the Incentive Compensation Plan does not purport to be complete and is qualified in its entirety by reference to the Incentive Compensation Plan attached hereto as Exhibit 10.1 and incorporated herein by reference.

Executive Compensation

On March 10, 2023, the Committee approved 2022 non-equity incentive plan payments and 2023 base salaries for certain of the Company’s executive officers as set forth in the table below, including the Company’s named executive officers. For additional information regarding non-equity incentive compensation, please see the section titled “Executive Compensation—Non-Equity Incentive Plan Compensation and Bonuses” in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (“SEC”) on April 28, 2022. All amounts are expressed in U.S. dollars.

 


 

Name

 

Title

 

2022 Non-Equity Incentive Plan Payment(1)

 

2023 Base Salary(2)

 

Ian Mortimer

 

President and Chief Executive Officer

 

$

343,422

 

$

665,000

 

Sherry Aulin

 

Chief Financial Officer

 

 

178,619

 

 

465,000

 

Simon Pimstone

 

Chair of the Board

 

 

124,702

 

 

(3)

Christopher Kenney

 

Chief Medical Officer

 

 

195,300

 

 

510,000

 

_________________

(1)
Non-equity incentive plan payments to Mr. Mortimer, Ms. Aulin and Dr. Pimstone are denominated in Canadian dollars and have been converted to U.S. dollars for purposes of the table. The U.S. dollar per Canadian dollar exchange rate used for such conversion was 0.7692, which was the average Bank of Canada exchange rate for the 2022 fiscal year.
(2)
The 2023 base salary figures are retroactive to January 1, 2023. 2023 base salaries were determined by the Committee based on a number of factors, including an analysis of the Company’s updated peer group which is benchmarked in U.S. dollars. For Mr. Mortimer and Ms. Aulin, the U.S. dollar amount of each semi-monthly payment will be converted to Canadian dollars at the Bank of Canada exchange rate five days prior to each pay date and paid in Canadian dollars.
(3)
On January 13, 2021, the Company entered into an employment agreement with Dr. Pimstone (the “Pimstone Employment Agreement”) for a fixed term of employment beginning on June 3, 2021 and ending on June 1, 2022, the date of the Company’s 2022 Annual Meeting of Shareholders (“2022 Annual Meeting”). Dr. Pimstone transitioned to non-executive Chair of the Board following the 2022 Annual Meeting. Pursuant to the terms of the Pimstone Employment Agreement, Dr. Pimstone was eligible for a non-equity incentive plan payment for the period he served as Executive Chair of the Board during 2022. Following his transition to non-executive Chair of the Board, Dr. Pimstone is entitled to receive compensation for his service on the Board pursuant to the Company’s compensation policy for non-employee directors then in effect. For additional information regarding the Pimstone Employment Agreement, please see the Company’s Form 8-K filed with the SEC on January 14, 2021.

For 2023, Mr. Mortimer, Ms. Aulin and Dr. Kenney are eligible to receive payments pursuant to the Incentive Compensation Plan of up to 60%, 40% and 40% of their base salaries, respectively. Incentive Compensation Plan payments for each of Mr. Mortimer, Ms. Aulin and Dr. Kenney are based solely on the achievement of corporate goals.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number

Description

10.1

Xenon Pharmaceuticals Inc. Executive Incentive Compensation Plan.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 

 

 

XENON PHARMACEUTICALS INC.

 

 

 

 

Date: March 14, 2023

 

By:

/s/ Sherry Aulin

 

 

 

Sherry Aulin

 

 

 

Chief Financial Officer

 

 


EX-10 2 xene-ex10_1.htm EX-10.1 EX-10

 

Exhibit 10.1

 

 

XENON PHARMACEUTICALS INC.

EXECUTIVE INCENTIVE COMPENSATION PLAN

1.
Purposes of the Plan. The Plan is intended to increase shareholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives.
2.
Definitions.
2.1.
Actual Award” means as to any Performance Period, the actual award (if any) payable to a Participant for the Performance Period, subject to the authority of the Administrator (as defined in Section 3) under Section 4.4.
2.2.
Affiliate” means any corporation or other entity (including, but not limited to, partnerships and joint ventures) that, from time to time and at the time of any determination, directly or indirectly, is in control of or is controlled by the Company.
2.3.
Board” means the Board of Directors of the Company.
2.4.
Bonus Pool” means the pool of funds available for distribution to Participants. Subject to the terms of the Plan, the Administrator establishes the Bonus Pool for each Performance Period.
2.5.
Code” means the U.S. Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation or formal guidance of general or direct applicability promulgated under such section or regulation, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.
2.6.
Committee” means a committee appointed by the Board (pursuant to Section 3) to administer the Plan.
2.7.
Company” means Xenon Pharmaceuticals Inc., a corporation continued under the Canada Business Corporations Act (R.S.C., 1985, c. C-44), as amended, or any successor entity thereto.
2.8.
Company Group” means the Company and any Parents, Subsidiaries, and Affiliates.
2.9.
Disability” means a permanent and total disability determined in accordance with uniform and nondiscriminatory standards adopted by the Administrator from time to time.
2.10.
Employee” means any executive, officer, or other employee of the Company Group, whether such individual is so employed at the time the Plan is adopted or becomes so employed subsequent to the adoption of the Plan.
2.11.
Fiscal Year” means the fiscal year of the Company.
2.12.
Parent” means a “parent corporation,” whether now or hereafter existing, as defined in Code Section 424(e).

2.13.
Participant” means as to any Performance Period, an Employee who has been selected by the Administrator for participation in the Plan for that Performance Period.
2.14.
Performance Period” means the period of time for the measurement of the performance criteria that must be met to receive an Actual Award, as determined by the Administrator. A Performance Period may be divided into one or more shorter periods if, for example, but not by way of limitation, the Administrator desires to measure some performance criteria over twelve (12) months and other criteria over three (3) months.
2.15.
Plan” means this Executive Incentive Compensation Plan (including any appendix attached hereto), as may be amended from time to time.
2.16.
Section 409A” means Section 409A of the Code and/or any state law equivalent as each may be amended or promulgated from time to time.
2.17.
Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in Code Section 424(f), in relation to the Company.
2.18.
Target Award” means the target award, at one hundred percent (100%) of target level performance achievement, payable under the Plan to a Participant for a Performance Period, as determined by the Administrator in accordance with Section 4.2.
2.19.
Tax Withholdings” means tax, social insurance and social security liability or premium obligations in connection with the awards under the Plan, including without limitation: (a) all federal, state, and local income, employment and any other taxes (including the Participant’s U.S. Federal Insurance Contributions Act (FICA) obligation) that are required to be withheld by the Company Group, (b) the Participant’s and, to the extent required by the Company Group, the fringe benefit tax liability of the Company Group associated with an award under the Plan, and (c) any other taxes or social insurance or social security liabilities or premium the responsibility for which the Participant has, or has agreed to bear, with respect to such award under the Plan.
2.20.
Termination of Employment” means a cessation of the employee-employer relationship between an Employee and the Company Group, including without limitation a termination by resignation, discharge, death, Disability, retirement, or the disaffiliation of a Parent, Subsidiary or Affiliate. For purposes of the Plan, transfer of employment of a Participant between any members of the Company Group (for example, between the Company and a Subsidiary) will not be deemed a Termination of Employment. Unless otherwise set out in any written contract of employment the Termination of Employment shall be deemed to occur on the effective date of any written notice of termination delivered by either the Company or any Subsidiary or by the employee to the other party and shall not been deemed to include any subsequent period of notice where the employee is not providing active service, unless specifically required by applicable law.

3.
Administration of the Plan.
3.1.
Administrator. The Plan will be administered by the Board or a Committee (the “Administrator”). To the extent necessary or desirable to satisfy applicable laws, the Committee acting as the Administrator will consist of not less than two (2) members of the Board. The members of any Committee will be appointed from time to time by, and serve at the pleasure of, the Board. The Board may retain the authority to administer the Plan concurrently with a Committee and may revoke the delegation of some or all authority previously delegated. Different Administrators may administer the Plan with respect to different groups of Employees. Unless and until the Board otherwise determines, the Board’s Compensation Committee will administer the Plan.
3.2.
Administrator Authority. It will be the duty of the Administrator to administer the Plan in accordance with the Plan’s provisions. The Administrator will have all powers and discretion necessary or appropriate to administer the Plan and to control its operation, including, but not limited to, the power to (a) determine which Employees will be granted awards, (b) prescribe the terms and conditions of awards, (c) interpret the Plan and the awards, (d) adopt such procedures and sub‑plans as are necessary or appropriate to permit participation in the Plan by Employees who are non‑U.S. nationals or employed outside of the U.S. or to qualify awards for special tax treatment under the laws of jurisdictions other than the U.S., (e) adopt rules for the administration, interpretation and application of the Plan as are consistent therewith, and (f) interpret, amend or revoke any such rules. Any determinations and decisions made or to be made by the Administrator pursuant to the provisions of the Plan, unless specified otherwise by the Administrator, will be in the Administrator’s sole discretion.
3.3.
Decisions Binding. All determinations and decisions made by the Administrator and/or any delegate of the Administrator pursuant to the provisions of the Plan will be final, conclusive, and binding on all persons, and will be given the maximum deference permitted by law.
3.4.
Delegation by Administrator. The Administrator, on such terms and conditions as it may provide, may delegate all or part of its authority and powers under the Plan to one or more directors and/or officers of the Company. Such delegation may be revoked at any time.

3.5.
Indemnification. Each person who is or will have been a member of the Administrator will be indemnified and held harmless by the Company against and from (a) any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan or any award, and (b) from any and all amounts paid by him or her in settlement thereof, with the Company’s approval, or paid by him or her in satisfaction of any judgment in any such claim, action, suit, or proceeding against him or her, provided he or she will give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification will not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company’s Articles of Incorporation or By-laws, by contract, as a matter of law, or otherwise, or under any power that the Company may have to indemnify them or hold them harmless.
4.
Selection of Participants and Determination of Awards.
4.1.
Selection of Participants. The Administrator will select the Employees who will be Participants for any Performance Period. Participation in the Plan will be on a Performance Period by Performance Period basis. Accordingly, an Employee who is a Participant for a given Performance Period in no way is guaranteed or assured of being selected for participation in any subsequent Performance Period or Performance Periods. No Employee will have the right to be selected to receive an award under this Plan or, if so selected, to be selected to receive a future award.
4.2.
Determination of Target Awards. The Administrator may establish a Target Award for each Participant (which may be expressed as a percentage of a Participant’s average annual base salary for the Performance Period or a fixed dollar amount or such other amount or based on such other formula or factors as the Administrator determines).
4.3.
Bonus Pool. Each Performance Period, the Administrator may establish a Bonus Pool, which pool may be established before, during or after the applicable Performance Period. Actual Awards will be paid from the Bonus Pool (if a Bonus Pool has been established).
4.4.
Discretion to Modify Awards. Notwithstanding any contrary provision of the Plan, the Administrator, at any time prior to payment of an Actual Award, may: (a) increase, reduce or eliminate a Participant’s Actual Award, and/or (b) increase, reduce or eliminate the amount allocated to the Bonus Pool. The Actual Award may be below, at or above the Target Award, as determined by the Administrator. The Administrator may determine the amount of any increase, reduction, or elimination based on such factors as it deems relevant, and will not be required to establish any allocation or weighting with respect to the factors it considers.

4.5.
Discretion to Determine Criteria. Notwithstanding any contrary provision of the Plan, the Administrator will determine the performance goals, if any, applicable to any Target Award (or portion thereof) which may include, without limitation, goals related to: research and development milestones; regulatory milestones or regulatory-related goals; gross margin; financial milestones; stock price; total shareholder return; growth in shareholder value relative to the moving average of the S&P 500 Index or another index; new product invention or innovation; business development; operating margin; product release timelines or other product release milestones; publications; cash flow; cash position; procurement; savings; internal structure; leadership development; project function or portfolio-specific milestones; license or research collaboration agreements; capital raising; patentability; other Company, subsidiary, divisional or unit objectives; and individual objectives such as peer reviews or other subjective or objective criteria.
4.6.
As determined by the Administrator, the performance goals may be based on U.S. generally accepted accounting principles (“GAAP”) or non‑GAAP results and any actual results may be adjusted by the Administrator for one-time items or unbudgeted or unexpected items and/or payments of Actual Awards under the Plan when determining whether the performance goals have been met. The performance goals may be based on any factors the Administrator determines relevant, including without limitation on an individual, divisional, portfolio, project, business unit, segment or Company-wide basis. Any criteria used may be measured on such basis as the Administrator determines, including without limitation: (a) in absolute terms, (b) in combination with another performance goal or goals (for example, but not by way of limitation, as a ratio or matrix), (c) in relative terms (including, but not limited to, results for other periods, passage of time and/or against another company or companies or an index or indices), (d) on a per-share basis, (e) against the performance of the Company as a whole or a segment of the Company and/or (f) on a pre-tax or after-tax basis. The performance goals may differ from Participant to Participant and from award to award. Failure to meet the applicable performance goals will result in a failure to earn the Target Award, except as provided in Section 4.4. The Administrator also may determine that a Target Award (or portion thereof) will not have a performance goal associated with it but instead will be granted (if at all) as determined by the Administrator.
5.
Payment of Awards.
5.1.
Right to Receive Payment. Each Actual Award will be paid solely from the general assets of the Company Group. Nothing in this Plan will be construed to create a trust or to establish or evidence any Participant’s claim of any right other than as an unsecured general creditor with respect to any payment to which the Participant may be entitled.

5.2.
Timing of Payment. Payment of each Actual Award will be made as soon as practicable after the end of the Performance Period to which the Actual Award relates and after the Actual Award is approved by the Administrator. Unless otherwise determined by the Administrator, to earn an Actual Award a Participant must be employed by the Company Group on the date the Actual Award is paid, and in all cases subject to the Administrator’s discretion pursuant to Section 4.4. Notwithstanding anything else stated in this Plan, all payments of an Actual Award shall be made both (i) within three (3) years following the end of the year in respect of which the related services were rendered, and (ii) within the ”short-term deferral” period provided under Section 1.409A-1(b)(4) of the U.S. Treasury Regulations.
5.3.
Form of Payment. Each Actual Award generally will be paid in cash (or its equivalent) in a single lump sum. The Administrator reserves the right to settle an Actual Award with a grant of an equity award with such terms and conditions, including any vesting requirements, as determined by the Administrator.
5.4.
Payment in the Event of Death or Disability. If a Termination of Employment occurs due to a Participant’s death or Disability prior to payment of an Actual Award that the Administrator has determined will be paid for a prior Performance Period, then the Actual Award will be paid to the Participant or the Participant’s estate, as the case may be, subject to the Administrator’s discretion pursuant to Section 4.4.
6.
General Provisions.
6.1.
Tax Matters.
6.1.1.
Section 409A. It is the intent that this Plan be exempt from or comply with the requirements of Section 409A so that none of the payments to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms will be interpreted to be so exempt or so comply. Each payment under this Plan is intended to constitute a separate payment for purposes of Treasury Regulations Section 1.409A‑2(b)(2). In no event will the Company Group have any liability, obligation, or responsibility to reimburse, indemnify or hold harmless any Participant or other Employee for any taxes, penalties or interest imposed, or other costs incurred, as a result of Section 409A.
6.1.2.
Tax Withholdings. The Company Group will have the right and authority to deduct from any Actual Award all applicable Tax Withholdings. Prior to the payment of an Actual Award or such earlier time as any Tax Withholdings are due, the Company Group is permitted to deduct or withhold, or require a Participant to remit to the Company Group, an amount sufficient to satisfy any Tax Withholdings with respect to such Actual Award.
6.2.
No Effect on Employment or Service. Neither the Plan nor any award under the Plan will confer upon a Participant any right regarding continuing the Participant’s relationship as an Employee or other service provider to the Company Group, nor will they interfere with or limit in any way the right of the Company Group or the Participant to terminate such relationship at any time, with or without cause, to the extent permitted by applicable laws.

6.3.
Forfeiture Events.
6.3.1.
Clawback Policy; Applicable Laws. All awards under the Plan will be subject to reduction, cancellation, forfeiture, or recoupment in accordance with any clawback policy that the Company Group is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable laws. In addition, the Administrator may impose such other clawback, recovery or recoupment provisions with respect to an award under the Plan as the Administrator determines necessary or appropriate, including without limitation a reacquisition right in respect of previously acquired cash, stock, or other property provided with respect to an award. Unless this Section 6.3.1 is specifically mentioned and waived in a written agreement between a Participant and a member of the Company Group or other document, no recovery of compensation under a clawback policy will give the Participant the right to resign for “good reason”, “constructive termination” or “constructive dismissal” (or similar term) under any agreement with a member of the Company Group.
6.3.2.
Additional Forfeiture Terms. The Administrator may specify when providing for an award under the Plan that the Participant’s rights, payments, and benefits with respect to the award will be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of specified events, in addition to any otherwise applicable vesting or performance conditions of the award. Such events may include, without limitation, termination of the Participant’s status as an Employee for “cause” or any act by a Participant, whether before or after the Participant’s status as an Employee terminates, that would constitute “cause.”
6.3.3.
Accounting Restatements. If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws, then any Participant who knowingly or through gross negligence engaged in the misconduct, or who knowingly or through gross negligence failed to prevent the misconduct, and any Participant who is one of the individuals subject to automatic forfeiture under Section 304 of the Sarbanes-Oxley Act of 2002, will reimburse the Company Group the amount of any payment made under the Plan with respect to an award earned or accrued during the twelve (12) month period following the first public issuance or filing with the U.S. Securities and Exchange Commission (whichever first occurred) of the financial document embodying such financial reporting requirement. Unless this Section 6.3.3 is specifically mentioned and waived in a written agreement between a Participant and a member of the Company Group or other document, no recovery of compensation under a clawback policy will give the Participant the right to resign for “good reason”, “constructive termination” or “constructive dismissal” (or similar term) under any agreement with a member of the Company Group.

6.4.
Successors. All obligations of the Company under the Plan, with respect to awards under the Plan, will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business or assets of the Company.
6.5.
Nontransferability of Awards. No award under the Plan may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution, and except as provided in Section 5.3. All rights with respect to an award granted to a Participant will be available during his or her lifetime only to the Participant.
7.
Amendment, Termination, and Duration.
7.1.
Amendment, Suspension, or Termination. The Administrator may amend or terminate the Plan, or any part thereof, at any time and for any reason. The amendment, suspension or termination of the Plan will not, without the consent of the Participant, alter or impair any rights or obligations under any Actual Award ​earned by such Participant. No award may be granted during any period of suspension or after termination of the Plan.
7.2.
Duration of Plan. The Plan will commence on the date first adopted by the Board or the Compensation Committee of the Board, and subject to Section 7.1 (regarding the Administrator’s right to amend or terminate the Plan), will remain in effect thereafter until terminated.
8.
Legal Construction.
8.1.
Gender and Number. Unless otherwise indicated by the context, any feminine term used herein also will include the masculine and any masculine term used herein also will include the feminine; the plural will include the singular and the singular will include the plural.
8.2.
Severability. If any provision of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceable for any reason in any jurisdiction or as to any Participant, such invalidity, illegality, or unenforceability will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the invalid, illegal, or unenforceable provision had not been included.
8.3.
Governing Law. The Plan and all awards will be construed in accordance with and governed by the laws of the Province of British Columbia and the federal laws of Canada applicable therein, but without regard to its conflict of law provisions. For purposes of litigating any dispute that arises under this Plan, a Participant’s acceptance of an award is his or her consent to irrevocably attorn to the exclusive jurisdiction of courts of the Province of British Columbia, Canada, and no other courts, regardless of where a Participant’s services are performed.
8.4.
Bonus Plan. The Plan is intended to be a “bonus program” as defined under U.S. Department of Labor regulations section 2510.3‑2(c) and will be construed and administered in accordance with such intention.
8.5.
Headings. Headings are provided herein for convenience only, and will not serve as a basis for interpretation or construction of the Plan.

9.
Compliance with Applicable Laws. Awards under the Plan (including without limitation the granting of such awards) will be subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

* * *


EX-101.SCH 3 xene-20230310.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 4 xene-20230310_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 5 xene-20230310_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address City Or Town Entity Address, City or Town Soliciting Material Soliciting Material Amendment Flag Amendment Flag Entity Incorporation State Country Code Entity Incorporation, State or Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Entity Address Address Line1 Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre Commencement Tender Offer Pre-commencement Tender Offer Security12b Title Title of 12(b) Security Entity Address State Or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Security Exchange Name Entity Address Country Entity Address, Country Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol Trading Symbol XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Mar. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 10, 2023
Entity Registrant Name XENON PHARMACEUTICALS INC.
Entity Central Index Key 0001582313
Entity Emerging Growth Company false
Entity File Number 001-36687
Entity Incorporation, State or Country Code Z4
Entity Tax Identification Number 98-0661854
Entity Address, Address Line One 200-3650 Gilmore Way
Entity Address, City or Town Burnaby
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5G 4W8
City Area Code 604
Local Phone Number 484-3300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol XENE
Security Exchange Name NASDAQ
XML 7 xene-20230310_htm.xml IDEA: XBRL DOCUMENT 0001582313 2023-03-10 2023-03-10 0001582313 false 8-K 2023-03-10 XENON PHARMACEUTICALS INC. Z4 001-36687 98-0661854 200-3650 Gilmore Way Burnaby BC CA V5G 4W8 604 484-3300 false false false false Common Shares, without par value XENE NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports xene-20230310.htm xene-20230310.xsd xene-20230310_lab.xml xene-20230310_pre.xml xene-ex10_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "xene-20230310.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "xene-20230310.htm" ] }, "labelLink": { "local": [ "xene-20230310_lab.xml" ] }, "presentationLink": { "local": [ "xene-20230310_pre.xml" ] }, "schema": { "local": [ "xene-20230310.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "xene", "nsuri": "http://www.xenon-pharma.com/20230310", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "xene-20230310.htm", "contextRef": "C_db261cac-5c22-4d69-9803-9c4174ca2402", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "xene-20230310.htm", "contextRef": "C_db261cac-5c22-4d69-9803-9c4174ca2402", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.xenon-pharma.com/20230310/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-007858-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-007858-xbrl.zip M4$L#!!0 ( ': ;E;1K/E&>2( ,.? 0 1 >&5N92TR,#(S,#,Q,"YH M=&WM?>UWXCC2[_?]*_1D[^Q)GXN)7P&3[GY.FD[/9F'_CN"+T'+<&Z[I'=UCF0!7JWWDB"OBT+'Z5)4U= M[QRIAW-%\Z5%'54TKQ;E.IIN:V:E4HF5LOG7XWKY.;E;6T],L8TJBC"\C$)#3./KS MZ^^7_I"-J':?#P&[)PIET_ WC7-:?4L9O.#94B1=$BA2U(O4)1UR]"G \L2 MVS2ZCPF%*E&^,,[%@X7=(WAZ\/%OY/V0T0#^DO8WWPX&"1Q#DJM70$/#XBOOGTXR-E=?J34X@AK/2JJ?>\EP81D^22" MT8ZHN.9QG]!QGOP7'Z6) -KEQRD-$&GZI)?>'1_(9@-^4[X4\"R-Z 0%B\'3 M]_RNCW4SH3[R(&"Q_#B3/,*##P=?_N/8MNEV*-5ZIFMJMFY9FFO[H:;[1M<* MG9X>='L')*8C;(7Q_FD,XYX,8#R"1F=QP.Y^8Y-BC'?Y!0MA]/\)/+-C^-37 M'-^$2H..J[D]0"G7MXVN[5/3ULV#CSI(B=,S+<-Z?S37M>4]-1J@"\K>AP'Z@?&NE"+?OL@!8=S1? MAVJNVH;\FB5C(;])#.P7@Y.4>NK@BE>99&CYC0?X/>1,$-D%MA0B!F>_S;/O M_LL?RY_F:T^!@$E0?@-0$#F:L8]3*Z:7[\V>3;L9/%"T?%)^+QLYFB--2< MDN?)J*]JD&W0B%_'?1_:80+5.TMI7/;43Z)$].<[=COD.=.@E,_ZJ6#:K:"I M:OF6H3T'<08 C2K]M1 A\?R>75R=7IY48HJS>4E92]/!W\ M<7%V=79Z24[./Y/3/P?_/#G_]90,OGW]>G9Y>?;M?-_)O6@6UB#WOT\N_WEV M_NO5M_,6^=P>M&&JY]AN2>*UD6VK?2=^6HK @&Z7U*-A;L08/ M"(S[(H$I+%?9RM1X%67E#+O:Q>V;ED4$WQ'3\C("[X1&;A0 OWR[^$J6*>"Z M#1XLGR7U?)BQV;JN.29,Y6R3,LVSF*/U.EW+IK[A@/__HLE09695!JWD]+;F M_)%3^4+>[\_SMH2:&^U_@YH-:NX$:F[4%P"G\>+T_(ID20D^9#AH['@.8<&3N_\(8VO&:ZZ MX&/#M>Q&ZRN.ZB^Y4*?T@,O267:%?X MI8W#USA\#U%MUJ3YHN#S XKO.3W/"0Q#LSWJ>&#@H?K M*KY:8+Q@USS#Y>?\')Z\OEZ_C&P/2E MU8#PF)SE&1D,*;@OXMW&1&6[@VOB%&_);*VML\CN[=!LD?<;IUE.O8@MDU_, MV2G%"/N,"3OZL2RN1722C'.H_XX%QZHM0Y>$+EZ X4EJGF4;OMLSJ=/5-Z,47WC$ MH&V/B;I+MZX;FM7I]+J-@.^^@(<>LW1J.)K;-7J:K;,.S-BIH]F]T+%\R_,M M<^WE8"7@5_3NK,C_]"7ROPUI=P$;.AVCY]C/$/='G*&N[%S-?2$U,ZSG'/Z> MM&QV!B^]'5RD^I8/F2#_&@N>!5RN7E7EY+6(W'7>(I63D,RYF._>E,5I=.L! MW1HDHQ'/**/O2,'\OF']V<4E.1VF43)AHD'139)UWV,AYTEZJ3H_% M=LRVN4/!G9_HUB^+:#[,W"UXJ@NARMV!PX8M#5MJPY;'T$Y_"[.WNL#C-W&5W-9^R>/36,346R5)M1YBZS53+/70[1@]9FKPQP&Q MERO:ZK M=2S=IYX9=$W/WZ@HRLC5-_%=)#=<'M5Q?YDNPP*X3(<5U'^-[A-FC6=#,DBB M\+RXL2 M6ZPGOPUYW9$UY=(1E>DN>AO=T.4>ZU.=4;M&J45;/L=A=R:&^SJS\%R;@IG% M%\POQQS3G[P+\39[2B)S>,7^,!R:2;V'(?9:]XMI.8]<:N];H M\;/U&"P70=/UZ+(1_,4,Z-W;)54["SO;$O*/O]^9NN$>9^2*12P=)G&Y("[/ M;HW&*/SD!%1'\J=/#E]U"MBQ>A8-M(X56)KMF:[F&3U#LQUJ.@[U="NTUW6C M,'2&PWL+CE-'7Y5<5NOAO7O5O#'(54HY;3T7S* CWH=4PW M=-:5O=\3,#??4>?>1HZCW;,UR]+U9VXX;B#\!;0^3W)RDJ81>"Q@$[=V/L5& M^[QW^SRWZC-] ?>;B6*;IY!12_A*U8RH17A(U#DFX"IC))Y$-"M/J]C<9L]M MCK#9ZOF6MGJN#=S+YJVOLCE[PP'X(?-_R#.':)J*)!4<4[V]Y(YX+$IN46_Q M(6HWZ6F_D9!'Z(+SC'"L(@!]SA-0Z=$XRFG,DG$634A&X:'W&*Y](M*_!<]!)S -?AP7*;O9XJJGER211P$5V<$ MXM& AT:7#+Y<$-/2VU!PBP>H;,\0-O:A7O;!\QS;"3VFA9:.VW #IM&.V]/< M3K>KZY[K]'RVKGVXA!F,#V(>7W\%_P75L MQEF6C9EH;$=C.QK;\23; 4ZBE6@AD@@5S MHC:]'D6Z*<7"((A7_[&5L\TME*VW+-;#NA]=%3-6EW V4(E]OY)'W"!3;[L_ M97?"?-Y"Y6;B%Z M,5[538?/BYM0I EFY<0)/%WH%?PR?'\4R7M=]PUEYC395;_)"XJ[1L6S# MQGL'=)CAFHZI>9T>UV2L]AAQ+,V--/O6)K= M8X;FA5Y7TW7?""W=-%VGLR[B%.ZE\BMK#S=_GIZ?-I#20,I6.5)S5*&F95O= M$/P8VW4B@;S[\4S J-E((;7&%B"L=[F0UP" M3'$_%LU(P$(>JPLZ51:Z[BRYIGYV.[U%#A'1N\?R, ?=/989Z>5+T!R 0(I7 M?.(V4;6>:'J:N:3.N45%5;F]4#FN,<[>KU3?OK=.U C5.D)U^H" O/ ,A!>G MAQ@>Q:N?\)1DQ]-LM^>@[6$:N!"AY7FVU?$V=+59.>)?Y8 ':KQ-9LBN')SP M1O3J+'P$?EL NDNQG"]LH1T"4K.(^3D@=9S(!?1QQF0IH%FQ41=*9EPNJJ?0 MJ21 899M11-L'.,Q _RGL8^)Y]27IX]BX2RG<4!%D*DM MNL%#J_?6(9VNWEG;LUO&7DFT 57J"/PO[-B9"BZ>%U/[^ ME5W-4.NU7;>SZN &$!+=WJ&#&Y8L!NS893^U.[CK+&2B&OLR@-[Q^ J\_(W+D8R&S#SYS 2YZ(C+T] = ?\KCXH1BD1V3TZAP MX*M%C_&,MX3'N4P3AR>+[^$\F<49A>(3 D2-*2MVT3CC67LO_+P-G.N7WVD9\L1BF\Q MAN_](3'T%C%UTVK)N;Q?%1?<,8)GF#!RB,_4,;[^\:#\6?T0'$\C 5Y"18!? M@BD,S;WY"9_/O?4GBU$NAQ0&Z[.Q-!<9BF][H4T,GI2CM&/V0 8CR+/9' MY'Z^OD<*3MMH$USR>*Q*#!#>9K(/10%(DJVWBF*"1317YQH*EC&)?30.H!,W+$I2Z?L )4#(DQC3V 2['D?*X9G] MK.*GY0.MK%.VT,(P;X;]0::W*O'5:K697#E.!2@@G9-*+C;])I-5]S^04?I\7?BZ#KP)6!W MV'<:)W*U$&7\KB4CPJE(@K&/>'6#O$/_ 9_'R4U!/F^<(8NR*J5:) %NT>+\ M$C7>LB+H'J,8I 99BGA!--7L_2)5PJ1C+RHW)[8D+)(0T+7XF"8JQ"V;\<'9 M5;W(* X=#Z+%(%.,Q)3G1T*!%H$V@&C9D*?S78<:_@< EH3CV"\'C ?6ADG$ M$] CYN,MTW.=@YZ!-#/%_D)XY&0AK;&,0>'W,/> K^A9A187#RXX<$8 MBTP?024HSQDH$5,A?G9;(3PT4924OTV_^(++PV>4J5M40-2M@./F:1**9(0Y MG6"B>5HL!U2_8M=D&:FB4E_Q0V,4]M,HG%2\1ZJFES.W0?J!Y%"B>(O@TE-4 M^;UB%J3TWO),(GL4$8^5'HVJ^MW4HH"BKS)!2LA5&RC8LU=7O8DKSP Z IZ# M]R87U.:Z42RK)3]4]P* M]FIN%FBSLX&SX_0,9@G3)H"$ (=5>?J%L59H#KX M7'"Q=0X'8BP8.L%CVC*&UC'$] MDE95>N8P4D!47"=4QA?J/)(VXK&:I+4?X;*B])+]TO:J:4(\!J1*DD@N59:- M@E45-[-"FM2TD6^54U#IXVE]$3"=PA5;,E '! _ LB718 MV U%@R517^;TX!JP8'^-N5#4G+KDRCE2A"X:57H^70$&NY6BU2MX4+;(\6" M&.P/*%"#U7N*U17=RBK3U!)R4\J#M3*@P=125-$=< XEKDV^TTD9DBYD M,_'!#$N8S!*T;IBF N\6<\0')-"#^6"<$)RJX5,:3]O&6$N.-DA-M5;Y#PT\ M[B4\SKQ&-,2+88PAO2FD>.K=X>P'1#? R1V877@-RBG$*T7^T5C)-/E*3>N4 M(Q$D3'D '#2)BR(+#+J!-EX>GY25?DA5(>];?WRN5*/0JD:N]U>NE=<<,/"$ M>5IUA:>GTJ+49D^9ADS%,QT+#*>@K'EJ12%B.+>();3_!4#/0ZY2SZ4C 16" M&SY!0R%8R 2>6%6ZJ8]&W_.<^AB,!J>"H6!C;OF0>^#2XJ;I(ECB)]@;.?W MF@"" ML8;3HWQ2605,$;)2Y=%F$INP(KGB1C(:48%[8V3F=I%.44#NPNK=XKJ=](?O M.[(J/:T(D;QP0;"--T3A;6\R]@[&@,=JHP1BLX#U@G4O'6UU)!H=&!?SQ MKB?L05:DH>1X $(P795=KH7JJ7U\#LVXGH-=G0;_*CN:L,5I$KP4B@QC M^+BI28WK\G106?6.R4DJ>$3,GA0FLTU.,#0H TF9FKGRO+V.UNSUU94:_3?7*^LO&R?.7JYA(\ MS(S'VSQ\:^'08V.M,X^;1-CR!*[=\MB?=1KQSQ)63,M^]DE_=1#@'>3[XLZL MG\[^!JM^AB3(D]\:L&K :H?YO@JLH,OXY,.!>5 ?X-KY Z%J!V4RY/5P;*98 MQ-W08C<27K/;G9Y;_0=WS3^7")UV]_DT*--0^V4.[H-4.30V=S?&-H^MW7=T M-^J#[IL+LC30WD#[$Z'=(I\P<'^)*Q23O0/QIU^I6ILQ-8"_LX"_N":S0@*A:MM6R3;,V MO(ZP;E=2?UYUYQM;S:YV47VUPB^;V^%IC&>6U'QRR$3>)SN..*;VVFX MF["TW[*YDXS.!VM9Q;2S0#IJ@ M$0^"B.W/:3IK'-*R(!W;/GK&>HVC9UY[5$MUH$F!WN-8E> 9$ 3O*/Z-Q3%; M>L34+O:\'NMZ.R:A.\G(.F44[!@_:XDXF C]E05([B8->@^$="<9V8#.V^)G MC=C91".V$0YWG9;59*7MFZ3N)&\;,'KS+&XXO-_FQC'T)@FZ.<9B]XZQ@+]X M^>*NW5]90Q7_S_U_ZJCL* 8!ORF[6[VZTVX[9N^7XP79"'B61G32#R-V5Y6+ MCNSC_XRSG(>3LCE92LMR*O)CR7T-QC[*^GBKQW9-JVMW37FI:>46G(H8S/>H]N0^ M^'B^^L+O/"%?17MZS'J+?,W:ZN@7>?CQ9WA6;A:05T #\Q)HCN;J$N@!C6G MH<+B(FCYTI#>X W?+";0%;1R4!;:J5X8+6\43\$$N&>.5U%AC-O:'1:/RINM;FA&]W>VX9HL ,^ A_H)M01<% MA?<_T?@'MB\;H/?JQ2JQL+Q**N09AF8GC )-IE@"XE/\M\&4/<<4"Z8NB1J4,JD'BIP4TP#L>B_TAZ-&/)5? MQ2JD=T G&4D%1]Q*5+/0$L$!R]ZFE"^%[3:I :(99@-IKPQIUEY VK=XAE*6 MA"FC5<4.(N-#$A) JV"H;)1&B5)@>BT8*U0Y'\[[2X=8AP(>_WCZZ^GLY9/R M954H.'XG70X*RGR'4 !X*.%C]H;'0"%BA#H PW^-H;JBPU*]61Q4'RG(-=58 M) 8\A(G2P3F)@081^40 'V81 &X4^2P',F2PM/^M^@J-[HT"WL=^YI&BL& ^P_=\8#&+,RIKQ4YC0]A5[C,4D%G'TGOT7!". MN:K2).+^1-8H.RK)#!8ZX- RFF.L(T8;P\(0?E%F$\-:^#KPD< M*HS96[-=!Q^1W>CBM5;.*U5BG?09IVI8D>#I%/6^@,XN\AU4)5/>Z@N* OX< M%.SHO[2(K?\B6\._2H5 E^9JO1I/UHW=,.H?!+WPKJ?,8@E1.; M)1&T5*H@U,+9C3(@4)N?P(Q8NG/7"8VR=FUB:_>#:W(J/Y5B=9,B=@]T'7P: M^50#'R(9@S^"MNY8U6KH4M&*%WQT3M.,]3.64J1*D7!;R<>]X1GW> 2 W2]+ M+\G*597WVJ[;0;=F::A?E7&-MJ[;#0$X\FR[BT:=NC!A MR_;A,'@WI7C[)YF*!;+]/93_+ KC%5>D9;=LT=LBJE.O,$EZ@ M.8+GF)KK[1-K09(\ES+VGFCEA5J6]>/K0=,;(SAE P% M"S\S.T/]CM(?Y:"U1*#9!/U487A]#_F0QAC&&%-KWV5CR*\-H1[L2 MM7PD^#$5,5I[C6DW(/K2.>+;!5%[+S"TX7>QV3(!>I/OF/]SADM[1;;"9YI3 M\H7#;/20@?L=!,4R H^+N#-"-/GST\7O)$C\,083WCV*)NL'$+;C'#],_ZT< MB'(O.7?'0(GAU/BFH)P*4#4:@HKV:71+ M)]GQ 3EJ:+8!Z5D?6#9V^LW/C1!?GOUZ?G+UQ\7IY4;HVD1\%5GO9VD(3*L0 M10"^2&>XA(F'X#EF )Z6N6PGOEP(-5S+;A4O7O,,,R1R,J09"<;1A/A49OSF MF-,@6)H(V8S'2 845(F"/,=LOB&-PC*;4$ZRB@)#)M@8DWED=72<#Q,!- C: MY+TG &&6K;O6D EUMS;;)\;W&I$4;5RY&7=:RUEVT[;ZCDK M5AVL)ZQWVVW3-E:5Z;2M;F]+JQ<8.2G_;8Y3WAWH6.\TRRTR]:&I<06,8=A(H&KZ^,;Z^]:C:5L.L.\O5&FEK#:UU8ZGKH/G[BN@-7QN^UI&O MC:7><:[6T%*K"Y=FYP.\A2N7=NBTZ^79P3\_X:]&V8\[DFO__LA+@LG'O[T_ M&N:CZ./_!U!+ P04 " !V@&Y6BF,_A1 # "U"0 $0 'AE;F4M,C R M,S S,3 N>'-DO59;;]HP%'[OK_#RU&IS+E J-2JMNK)*2+2;H)7Z5IGD -8< M.[,=+O]^=A)#: '13AH/8,XYWSG?N3FYNEEF#,U!*BIXUXO\T$/ $Y%2/NUZ MSR-\.[KK][V;ZY.K+QBCWGW_$3W" MTFFLZA1U7"A"HDH-/1PQEZ^3X4 M$YY0PM#(!?V&^CSQT2UC:&A1"@U!@9Q#ZE<^ERJ-596#)G(*^I%DH'*20-=K M9+($+CC.9T1FI$S$1@[;D2D@T5K2<:'A7LBL!Q-2,-WU"OZG((Q.**2FQ@QL M<;8,&FK3%*YBX$766@==CB7SA9S:0&$ 2PU:'PE)!\C9@0-2ZM:X4EV7+& M*=#M+!0D_E3, Z/8,K3*5._*..P$E;)I2@\0-F.F3>O7A$V[CNY?C7A7DKJ MT>7E95!JO>L3A,J!H5DNI$;5W Q$4G;C #W[#SN.V(IPU,+MR#?./,1W3]SN M!(-_(^$Z^RD2Z['X+ G75AN]LR_NSCDX*J+:-W'V@.WA8,QW<_JQH#N7(@"F ME9,Q68;K 0( --O0<5E-MP0.K M5JC<-:=9Y4:A3/U9/7;_/<]K>V2[WUN>_N"&VJIO)LHXL+0\1,U3Y7ASQ]6Q3<&\ M =!R:*/0?LS[0>-587TD/$65-]1P=Q6\=?+&?:$@_V&UT/6L7MS@S>;6@L9^5Y+JMKG^"U!+ P04 " !V@&Y6T=O> M_XH& O10 %0 'AE;F4M,C R,S S,3!?;&%B+GAM;-5<;6^C.!#^WE\Q ME_O2ZDI>=_?4J.TJE[:KZ-JF:K*ZU9U.*P).@I;@R)"W?W\V8(K!D&X2#/>I M!(;'SXSML3W#]/KS=F'#&A'7PLY-K55OU@ Y!C8M9W93^SK2>J/^8%#[?'MV M_8NFP=W#X!F>T09ZAF>MT9WE&C9V5P3!^>CI K[]\?H(CY;S8Z*[".ZPL5H@ MQP,-YIZW[#8:F\VF;DXMQ\7VRJ,-NG4#+QJ@:2%\GR"=W8<[W4/0;3?;':W9 MT5H?QJU.M_VI^_%C_\-Q_;;? MT0@7WZ;D-QU?NG5U==7PGT:BKB43I+"MQK>GQY&OIT9[R*-60[7;,X#0'/H$ MV:QKPAMM/>28R/0;C)K$AB!D,_-C MPM^<$S0-&+B4@M^\BXSZ#*\;)K(HC7:;76CL@AGW5_KC^[U#B>QZIDF0Z_;I MY9",\<;AF#Z]FUJ>9*-HBG2<6H;ET0GX1& M%TZ&N^D7.HRP>>^8S/E*6,GE%'5S. ]?,'5,]M_6,K=WI<**B#Y8-GI>+2:( M9-*+B:BU7OB'NE_4VF<\0581S;&^'9ATA%E3*UAH]Q@R2UX1W?L%(C/J@;\0 MO/'F?;Q8ZLXNDZQ<6A'55S2S7(_HCO>L+[(G3D*L<'(OA/K=!74J!F*>9X^#49&2M"#=1J3\9L(R-;D9,B:N>VOX@-R0O!:XOMW/9,[Z2X MLE5F3!%S%A?_<>%D_J(=13><;#BMG-!WN!)6[?/H9@BA.V6!F>; LM/"^CND4PBNRWZF_G5*_VY.(QKM.Z@RQ=AN@00@'# ^&!!CB=>.M MZ*KA* UP'VC;*?01@0-'\I$:%F"Q15,]0JDDSR'!KH>8,!'Z>:;./& M]@$ 3Z'5/I]< (=6L+=(I*I.LT$*3NI# ARV^HKD[9.BP$.QZL2S=,<>C!E& M]5A*#\'%494F& ^T;(@%(EB%><=MK9*\+&]ZI",'CE7@1N 4M(6PO4+NLFSP MB7)4 5AU:>?FIHHGG\AQ'V?T$ Q\-*!P%68NL;LB^LD4_H$V]V' QRGTD'TL MW;BA57'>]P'"J8Y& ;#Z$]+1"N6>DY1I)7R%<6B6BF' /QSEWV*8"A]H',@T MQ( I((\A?/<^\GVB/C!C$X,WBJ]W--P*-$P,!U]2T\+;!6^/B5XD5]MP1O& M^[\727]5HX)X=K4&YYSQL44Y=*4U')QI^KN%X)!?.*"1=#L7*+M;H>XO :>>^G(*R0#6.79D MAP7^^XX#OA)PH/>0J%)>2(@_CS]_GM@S S>?U@DC;R 5%;SG!"W?(< C$5,^ M[SF?QVY_/!@.G4^W[VY^1;B2=+S+R/OI M="\* ]Y1$-&QF;07\F01RW29XR,="]%1J! OD'LS>?]52REI!SK^W['>][KU*$_N8:F*L?N4';[02MM8H= M@JO!53[V?QC$P-='^%4G1P?7U]=>WOH=JJ@-B&8#[\O3XSB?IXLKE*%JX-R^ M(V0KAQ0,1C C^OIY-"RR RZXFRY"F83YBNHE\#N![V7A6G"1;#S=S1OAQU?C M%>;:Y_$]SVBV&?*90 -:8&2;#[J0,.LY:%X+M36I9?KYAPUEFQ1ZCJ))RL#Q M_IU5*G'E>99CM=_NX)IM/3/$QWJH0QY%WK#.@,<0Y\MAJ#,1%4!,.Z>01>GT M%!3.(? MU72,@!.T:&%3:*Z<3!^'BO5P#RR<6]@4VVO3YA4D%>A?L=XR3XA4Q%5.;^OP M(YA3[2P\>PX3&SLKK"9R U1%AFR(;];Z3]B4LCO$U43O/@$YQU/X#RE6V6(@ MDC3DY23MZ)JH/E &S\MD"K*4WQZD)E)XQ@N9"IGOJ6/<6F$@EKB2FX&(RUWQ M=*^:J$_"]3!&KZ,SN@TXSHA;AJ^);C^.\?A2NPL>7Q"44K5AZZ4YP-L7.1$K M?H[D'K)>BKG?OBNX MSK1V9MMT0\AE9.:R%"7;,:;9"IL;EALKTVC^W6T M"/D<2L)_*ZQ ;C\Q[LLBT5!&QB;>'N?LA9K)#N&EH41[;K2@+#:]9U(DM@37 MC"8L^281$EVNYUQ^!M!VDT5Y*C88!3I-%61DOJ& MT>6BJ;KL%U.,&)=-%>-,$@/_3_-&__ 5!+ P04 " !V@&Y6FQQF ML%@F T:@$ #P 'AE;F4M97@Q,%\Q+FAT;>U=6W/;1I9^WU_1FZE,25N0 M(LF6+Y+758KL9%R5>%RV9R?[V 2:9"<@@* !4MQ?O^?2W6B H.Q4[!@&,5,S M%DF@[WWNYSO/EM4J??X?XME2R03^%<\J7:7J^)*/"GNKK^A1@OW2J7N MJA.=)2JKKLY.S[Z]GN=9=6+T_ZFK<_A<5-?ZY4R MXK7:B+?Y2F;NX5E>5?G*/D]=R%0OLJM4S2L8P3-LPHU@L]25.C&%C-554:J3 M32F+W5&$G?[]]SJOKCM=\Y>1,*K4\^L5#&*CDVIY-=?520POPP2AY[__[?S1 MV?6S[["YY\^^*[[D8I1ZL=Q9C9F,?UN4>9TE,.HT+Z_*Q4P>G47TW^/KG>_. MCZ_W+^!&81=7LSQ-/MN*OKQ;ZIFN!+1Z/HQUG0[9AP[9!U;C8M]JW$*;LU+[ M59"9.?EZEB*&;E3Y)2[_GQS^_)?[U_=WOST3KQZ M?7OZ29;YT;3,3-=^>7D+B_L_+W%I7[ZFOV[_^?.;EZ_?W;Q_A3OPT\WKSHHG M>MUFQ2=(BZX>GEY>//GV>F<;$FV*5&ZOYJFZ"[? 3N37VE1ZOG5CHL=.3"7+ MZII6^@269V6N9M*H5&>J=U^:V<$@'CS^-MPHV_Y?L5-97JYD^IGVJK6N?E%U MAHMR0FM[;[_=XWW/LH>K^?CRXOSQDT/SP\<7EM[".Y_X*!B>A/:"_ M<+5I71(5YZ6L=)Y=01^JI#%\KCOSIBZ+W,![^5Q42R7>I#)S*_)5'[%OGI\* M\=[.2&@C-'Z?J$14.?P=EPHNH3!+6:HE$"55BK5,:R5DEM!"F#J.E?'K_:IBZ$J9ADW (;7__PF)UZ._ MA';UR7A?W:D:#N&Z.'#"]4+-=::Q,S,6>O7';OG3T[-'EX.[Y9.$\F/SF[O'Q\^?#\["G?\V&)*)_K]#/?BZ__XLO\UQ.NF[BJ92IN-K),1D*Y M>.^2:[%2,@/IAL0AE);>L#@DLUCAWSI/(I)U)*^!Q#401WJ.#X/P)+=REBIZ M6;R!NZ%C#2)1): -%DY[FC,UB4E.XI)UMST$KDY4: M*2T&*@RK6=@%%4 #@2JPTFD@DN@2*FVYQ7'"][:>(]76!LRKS%-_%WXW[(H7!@2(>:,T3L1[0 M(1P0L7XP$>LQ$>OO\]$*S4C,:'I([5X0(Y'DZ7EI7Y"S8S6$>(%FNI4Y)^4==/T%]78,XBA(K")2!+<"<"O&NK?*C M0-GR7T4]BK^"FS1+M5DJ1VK=$E./2L;+'O/"1&\'=(P&1&\O)WH[)GI[FR(41/IE,Q5L%NGN-$F5"2OGYTR>/(C39RA6YQX&^OE5S52JD M@F2)-86*]5S'T#,;1[U,BBV4HE2+.F7K EH6%%M2-SI-!1L7R)F^;%X/7XG( M*K &2I6$#<$S1(I3L:AU0A09>EVH3)7P';$(E)"%+(I4Q^Q8WXJBS%=UNI!H MO.!1W-]Q8LTC(%N7Q'R@@;4V=H[XV[Q&,X=(U4*;9FC!0&G5R'IB:AB+6J%= M)5O@4_"%*HW"7^\9Q\1B!G1_!L1B'DTL9EPL9K725:5&RF(-)DM!$W M-EHV:QP5=6EJ=."*+(R.+:-<<)U'\ M165 XMXL)70:J[H"034U((G'IQ$1S,8KATUHD,J=V(I4\"M;$WX?AWFE*R!_ M\?X]EYE,I/B^-G"RC $]PB^$$3=Q]95-?-\TQ=%;4+QN8:]!Q;J,1'PJ;D\> M/CP.E:T(=0'4,VRT<>[]LJ1)5?G$!@>TIP-B@T\F-CA"-BA^A D5(Z%_/98H M-TUG>7DC2WC61&C1-SK1LM3*L&'&A^7\T>2'B00>" E\.I' ,9' %]I8,^XX MZ9_$W#!X&7[D'+,!*:7MA-T)TIOHJT#.C(#HJWG9Q-Q'1-Q=7FJ(R6M M($JJ.Q77F"P+*C6(CK$JHR#6V4Z_F\Q+XG8D-DM%CY&3#J.0USK!]!1MA,G= MR^UHYBI(+'8D%[J;P:;B?,+7#,BVZO=:94V."KX0.%(G>_? 3MB0*/&4_3L+_"K=R1%UUUBCPC"T!NOV4_3'HLS(DLCJEVXV+ MK.[<_'%25TJ[H_F15HYV3(>L P^8NJ3L!:>Q%\&JQ"5,I-22*>4*[@X07GB) M3)JEBI5>(^*#"+&-K'SKG5I]M/E4B)L>PBM6 M1Y.R*J2\1*( M.P>Z52.5&J-]KO98IQ8X9!JOHD$JT<039SQ/E'/)I&!+EG!+JQD4Y723]:,-H MW58:/]//Y8";@U *WY?*H5OD4RC#0,_)D"CJE)LU*HKZ'JZ4JL:,UTY1K3Q+ M:2VW%9E;ES"I$HACH4I4\,71^=G9M\4#W)JF9 M3 *]^.ZRW^7W01-R7[)$@^)^,5'I 9V\(5'I*7UL9%3Z3OP;[C[6\@+9;BPU M@;J46M[!&WFL,3LA,W7)-#=+W)=&Q355OTBURRLCRX!:Z7HE\AF0$PNTP/#J MF:641#8I-V%#:61MBAV)QHB+3^9U%?C3K@25/I-I*N8J08"VB$T7G,F;YC&- M%C,C(IL6L7)9<&CF8)<93 V6)[ 64^<-DVCJHA&>W0_]X8!Z1TPW@ MW./4?.O]S5&,= F3Q IQ&6@@%4X_W+.>/!7@A;3):-ZA[0).R@54NIM%U>7B MXYW%14RZ[MEIOMLY.II?<8<'VR^5*6!UM1TF\FVX(?&RNS@8FD/Y-QBB(Q>E M<@LMRX@'CRU9#%=*N^F;R<2[!T2+!L2[+Z;LQ''Q[J8B"%*^EYY%C).)2X%0 M/S+, '0)BB?VC](;G;#P"M#-:H-QCF$ I*M3VF$M]S%JZ#DHOH*\":@PT"A? MB\7$2]3KX$\EJV4DFIS\"!ZM=&GU.ALTA,GK%J;#0:9:2(\ T8,$$(_F<2K$ M#\A3>JK. EL$EF3FBG*& CG!M>N92[,<6UC2U4SMU$FP'/.H'1-D7]M!(@D& M>\RXM10Z!!-4,&%\8.\)/17_RE(J$XM\=J.QI"SHQ;CNF@>X*1$5T=:RD7'5 MF1P.9F_K6)X61M.,!,.@8F#3@K%VA9K/N42L2-!59$%K79&V)\#' MULH*)TJS?! LB74^M3?0RC$^D=:*.RQ=8' M+R6/EU=/9<&H'1 P8UWYA-@F M&LV.=8-FVG97VE"#!,W+800\8[AS:W@E J&!=L#!%,,(MBT!S&$$I^1+^TPY M%5/-W9%)'GTU=X>53O$%:J4UAK=.^OI(./6D<0QH.P:C<3P86 G>+WKQ\['D MK8,H^MYY)$CHPV@:#T3=1:\F#X4'\19'^,O!*&ACW'ZGE!V?BOX;7-?\F/@&\ 07IE'!E,)J M4U;!PU'76:73D"AXI<\[*4VPAHV)N!46W=FS"?Q^V*1B0&+(L$ ROC ?$C>. M-(R$(P&M>55Y.DYDL=Y7QWX/X>V)A7"_-<3(%SDRELCWL*BE1 8!?Q3Y!MD- M4C_"G%1$PEH\$CA.F1)E/R3%:EDA59)!L/'8H^V-*O=:E-HF.[A-:>*#/?!:R2:"OB-1XBX 3+Q84K62[N" MY".G8_7+'Q]'Y#S)FL-(THCTPK0VA-**0YKQTJ,WBV0-D#2@!?[-LW)XF@G> M2M[I5;W"D'U;GI)YI05^N<>W,Q&[PR9VP\)K^1+$SIM7X**,T9K7I\E$2%=( MQNL5]D&"!#D;K43L6@::A!\\W4.*9)&CD*:ASM(8H[ MJQKM!K>'2"5)LHST/Z6R=IVL>(0_<.6FX M4U')WQ17-IT ;@[IO]-C=EP8LF7"=<#.YNII4SG5N[ !A9KP!T=9_J *-X7=C4Q>Z0N[.W3U[1W!VUK"&P1" MLTKS(C3UX!.4J3R6!+C)I#.@[1B,"O/PX"/R]M*$L=S[O:YI!OLF(:/M!W6: M2XM"SJTXW8/N+9HG=YRLKBU*FND!J)WUM2B 0&AS*F[(!0_28+K=!2W'@F$] MX =LYNYI4V,>!X'8PIN+6I)GFP&_I,&X+4J?F"D4/CT.>B_D>2?WHJ&OW M6W2.OLZ#27AMDC)"2=YEGZCOO@T*W$[MA%E8-2<2&F.]_&O1?5VASD2- MG8J)*PSGL@Z(*QQZ@-2.+!B"UXR:-:">J>"4S%)M,-PTG#A#@Z-I+*2[1ZQ1 M.R7Z#N.#T/@D;:U>1+R1"[63?AB83=:JQ"=DEB'J.1("862*<3TNPJ6?R (U MTW?059*G\+0UY9 U M5[-@8T7V*[B?=E\*_8:)U*MB99_T)?O'$3E[JWF-!$ M,P^;9AYZ),CW>5:#3)+GZ7CH(_D!^O"T=BE$EW VRQ%9FV,!?WLRZ9Y$.S?9 M42.1U"4%<0#-FKNHSR!%HE?R#@M%-&&;9'KFM 6*H7KG/$$3_,A$PM=YA?XM.!&9KS7 OHQRVT2G=? F M=B-&@B +>$MSN&\A&R"*;HT;H(M7Y.W468Q>/X5(&4G-R$H*P]@S"B;IER [ M]7(X0@3=??>W1A26Y4.9(KZ6U9;;5-/)R4$?CHS/5)IO&.81J/8LM\I\*#1_ M9/F>?DF\B= /AFI]79VIL9LPF!Y%*;5$WD#"U16!2AC$1U%KB4@C/EC0.M=" M9*^ L:'KD-?*>KWX9#JDE# CC."Y;)^ZXAASN*-[?5-3V,V B<. ^-"PPFX^ M%RT68O3YT&V&^L(3NUM;]FLT7/73L%4FSVV>$&(&+W*9&K(&0_-1J#O88J M M8\X1VK;SDE>?8UN.16/+L4A#40_^5<0],;86,8@K@71?R1(1""G@8PV0[#P2+DQ1SUS6 M%WR*)3#P.4@L]L\B-YJ'@T%%MFPAK*;$J9[&;,)ZN>9[J_,1A2K4&!R.CR#4.-./#$Z,E;^9B:@CQ$MNG MP1<:-[:4<%6R!?0H\7K94+AKNQ@V7"82356#B,H?&DKCXU ;C$.:_+J&G@DM$I6FNU"18>NK!/TG?^@RM:.*G1 Z+" Q)?#J/& MULT'M9ZHGX%YWNU 9XA2G& 4:JX*2DN,8]2$DET#Z@2L4&)AW=#!H M,C_>W+P9B83D0620D@8YV#A%&X5L/,ZU9$7UBBQ.\D_?5+@>NE*(;>F<_G/> M1)*O5&5- !^^#;@"3JF^ST\5:/;W8IE2DP'_"]EEU+#PR''XJ)%=D)/BSG+P M2'L>18#T08YQ4B@?:I9OZ[ %;/;E!(N4_+1(Y[S<+K[CQL3+' M#,% 83K0S0D)R+PC%G; MMT]RAV\6%J!S1)SY\D_ZP]'YS%KH9N[+H'F(#Z" M\WW0!WN [KD7##G$GH[0)0TR?/C19U-P! TJ0QS](GYH,@A6RN)3!&K3;J^D M@?'.T#$+;$JK/#SM,?Y!7_F.!1"-JA^CPSDC M'H./[)[M+@ ^R,,S MH%^BF3'? /WGP0>5O73#O6QMV:PG 6*Z]#8QI>41;L2<(G@2J MN@]!L=H[2AZJZB\R0*[G)8KU%#_NPIM=L^@\K,J:W9'H^"1G,'QC*@LFU?@H M46!'08MK.FW[7<:47^E\J3;;L,'<0CDV P6'BOF@,=I. 'I.-)OBV[Y.2MVS M9-YG&5:=:CZ=1,.#\H-^.9'J_ O1V-U^/R6-_0I#M#_A1GSS_#U&.2PX:^<+ M$]=/.B]*I_'BHMI+9PE\2B).74[D:B2\I<"D::M^-V&0A#DXWQ<)WJ*WK<5B M7Z(U'?K66H]HE[:_-S9GIS+-A^W:UAC0B7+J)"RMD'?-5 ,KV5?DSE6H25R\ M4G?PR&\CZ\,B0(-8&G)=D3_*N3/W@!P&4*0A$EG+.-'CNF8^K5*,TZ_(CA#R M[(A!R *K:7<=?#D>1E"#E15'^IAX*C54(C+\@V.QA55$ UB:YAM7RC X"O@S M&]:8#%L.VX#=BIV?/CQ[>G-R?C0[/GIXW ((?5^2P7,+0B'YNADX=M*@AD-] M!J1!'7HRP0_0\2!X^^=7G!K/9DN%0F\%!FF@B1>!63 :F-(,:ZBQ$B&5HHI@]KL4&5;8(#,OI9J8Z>5Q=#AW_?BP(6.&>1> MT"NY9FT8*?&"CXJ%G2CB<([L@"CBH2($E)M'DT129' ^U M?#6_KV@DUW $BE)SA&._H2?97:"/24EH()C:)'79)F'ME"OR>7+C>[+&LETA MOM6$E==#/<&EP/9-3KD"X4SB8PH )"M3].E4@,FC-Y [,1R/WK!BV+Y [)6U M![_Q>-UC(;J3^#6<[1B,^/7HX%UZ[^6=^)E ' _TII\_.+U\^F"ZZB.ZZI>G M%Y=GCQ]=BJ)I5A-T9BL]D8;C7.V$ MWJ-61<5^>QLUZBI/LDV]L>6@RA2N$R*048,9P?:SX=L[ 1B1+ G+A4;SIWR MTU%69,)F)5LWRP-:MXSMV&W4A(6O9GI1PULVR)4^YK6QUJH&C]O6LN)0 NPZ M=_-&Y*#)/L]EU%G'$)^*%!QCA,R"4TJ>'H[,$$[&M M)DS8<'HU ]5/10&RL ,5]DCEG4"*)@W* ]HYB$#8,(S3+A3LGML-6G505MU. M-A#(!&IN/"ZY"Z+F$-O.&9M8UI"(RJ!8UE<8#O')Y=-_ YW&2XO9F^-A6^]W MJ%P??]L1C\#_39Q_=_$P!L-9" ,VUF-M1O@1K,,ISY9"@9T4P9D*3AT2HP8O_,YQ:-D+6<% M"JX4BS(>VOQ::9_@2%)Q%E9=V(6ZJ%).!GPLC0 M6>V"?WI]()Q7!S(M@A)PX*Z729MD?5YZIX*4>TAEYE VX+=JHYRI"BTVDF-J.+ MXX40NPHSN-@JK.[BIP<*_*?/*VCEOXL"V MVI7FR CL;./[4*C9Q!JBW+L5CVAWUJK<=G8J*#N^F]C6+\Q_ *=#9"I6QDCN MBC(LBE)3K-*]<"1H^I4Q+"1#DUG9NAWD7R 45UX; @.R:XZQLA$#P06V9>Q5 ME=6V\3SLFYY/\R +OS,Z$SW$778 9A2GBTL&O]J"GANIUYP!(<6F1$$\ "Z# M2U1MN%AH%Y&B6SYT1W'@*21Y7&-+J)L$VSP_%G# EHZ#6HC-,MK8Y'M6;))HAL1?!B71'+I%ZJ9QI@;Z#(;5CDB8 MZ0?09KJ]96@N9@)4SIA1D'H9FQ='^HU-5%LV\IYM]C_/5*;FF*71!X$M6U&^ M?TZD(K,9-DJASZ6R$$R6/0$;(O22B!6N#2-O(V!U>1U.&)K MN>0[T44=J[J!C$7)NN[2[D1F3X"KF+!8(CDU?8:.1!UVQYXE8Y MC3_0N[?1F8B/Q":OTR3T\[?&=NH&-[&A 5&&0;&A0[>EW31XG6\Y;V$U)HL: M9:N$8FE'@85!%:A RBQ$+BV;E7!Y+ 0_+0DP$7'<,HI'TCUH>SNQ,B!:(^&N M$:71J]L-9#8, +'BVDEY ?L+-%VN8T[Y*MW 'RR^^5M&"=GIEAT+C0 LJ$W['"[%'%$5S VB#BF$!Q;.TH?!7TS10TK:/SBV.Q@N.Y="GK M[3SZN2Y-90'"89W0JL+E4>8Z]<4\?/+ZN\ ( FO]TEE28'JHS^$:<1U V)_2 MMFU%E,2GP3F)_]DEKY\C)O)F@YEF])W< MU1^W"]B)8XE:F./J#IT5SD: #+9YSZ8"-,*C!+I?*O8^8&?T=U&7P.DQYF2E MRH4J(U* @6TE342YMRM$U$R:[W!;X"U5ZC$+ SYD5P[%..+MO407&%4Z4P1+F7-<*C 8@UZ %D\G6ZGJH N&,%$8ESA4% MGN=9NNV!D)@0'(9RQH>#X/#XP,GI#:BL">OL < ,7^H7-0]C+&1UDJB&LQV# MD:@>'WRD7T "WM4&[71.I0DHPEAHP#X/N5P1HFH9)"4TVJ=UM!9PG%Q]F79M M;RJM8Y]B.Z3M2#9K:_S:AMUTRIWZJC6-)YD K4#;5$W]H):C5Z;HUD5M%?1& M73;Y(URC,5#%&V-E*W>/S)MGLVMK3I]M64<.!:= (+42J!/4K!1&R\/V==*Q MPZE:OW/_A">B/*#[,2"B?.C!2D[V(O17N">CH;_O.VEPJQ5;Y@)\;_:;4:1S M$T;\?6[SC)V-S/N3R/E65X>3$#O?>/I@Q/>NC("%Z?'OKDP.G=3W A4\H$8/_K M>"3.2< 9SG8,1L!Y%UCI,18[KO8K91"U65E(,S0XW<4L;45 MO;5%S<"._UJ4V0$\K M9UXR+K.C918C&Y;MA ;3\,!MCJBKW(OEZT] JI0343;GPEG&'FJN*= M([E%N8N$DF1=].T'Y]VLZ%(F7&<=PS(MO9T0IX9T$P9$90\]L>)'##>FR_J3 MW(R'S'J#&4E[#5;!+L7I!1I(Q(+6I1$^740'T2XD-38R[GN,;#=+4,)3$,BU M] 1NKA)"^7"P!'G M7L&AEJ5:YSBKK9! R\JL@9D"\FLP,+S-@3"ZO0Z9PSU+&MFU8^:1Y1[[%1N( M[(JQ\H!%_%07XC"$8[#U_#"7QJ8L3JQA4+=W0*SAT .MO\^SVHS+C]+PA0X$ M-P;)^826&4T<:.VBE"N?QT*UF^94N(GI*"4WO<#$O,HAO/XD9Y1SW0!S&^M MN;@\/SM]T !SQ\><6]0K 4OK6L%JHWT,RHKI%:_Z'D MR."LW8Q8?@D+(FC.[8.GURK3UCF<;J.&R*!&3 4].?$7+JHV](XO:B"=<2 . M'$H?$W;R)S/7ANFJG0C2I_;6/CUP>G3;Y.(3%Q\O-F O+N#1O=AM^!B%QU&B MFLTX8Z7]N __IH/"SY@#99W:)/- !+,V1XM"3VAR:\SBGS%X/2OZ*,"!LBX1 M-,"6';D/!9 07VQ0G\-IV$<="[>9.P0NV )+CQHBMYMRW+V)?00MH%^8=Z+* MKYY\??/\OX3[3_"77^OB#W"@9]\A8,#S_WCVW;):I<__'U!+ 0(4 Q0 ( M ': ;E;1K/E&>2( ,.? 0 1 " 0 !X96YE+3(P,C,P M,S$P+FAT;5!+ 0(4 Q0 ( ': ;E:*8S^%$ , +4) 1 M " :@B !X96YE+3(P,C,P,S$P+GAS9%!+ 0(4 Q0 ( ': ;E;1V][_ MB@8 "]% 5 " >&5N92TR,#(S,#,Q,%]P&UL4$L! A0#% @ =H!N5IL<9K!8 M)@ -&H! \ ( !@3$ 'AE;F4M97@Q,%\Q+FAT;5!+!08 1 !0 % $$! &6 ! end